The negative enrichment of CD45− cells combined with a quantitative real-time PCR-based platform showed that EpCAM mRNA+ in HCC patients (n = 56) before TACE is associated with a higher risk of tumor progression [34]. The gene discussed is PTPRC; the disease is hepatocellular carcinoma.